Is NAD+ Safe? Side Effects by Route, Real Cautions and What Is Unknown

A study in PLOS ONE in 2012 measured NAD+ in human tissue samples across ages and reported a decline with age alongside rising oxidative stress markers. Reviews in Trends in Molecular Medicine in 2017 and Cell Metabolism in 2018 summarize the animal literature on NAD+ restoration through precursors across metabolism, mitochondrial function and neurodegeneration models. Two rodent studies underpin interest in the nasal route: intranasal NAD+ reduced infarct size in a rat model of focal ischemia in Frontiers in Bioscience in 2007, and protected hippocampal neurons after experimental traumatic brain injury in the Journal of Neurotrauma in 2012. A 2015 paper in Brain described NAD+ replenishment protecting neurons from misfolded prion protein in vitro and in vivo. None of this is human safety data; what it establishes is that raising NAD+ in animals by several routes has been studied extensively without the kind of toxicity signal that stops a research program.

This is where the randomized human evidence sits. These trials used nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN), which the body converts to NAD+, not injected NAD+ itself.

• Nature Communications, 2018: six weeks of NR in healthy middle-aged and older adults, randomized, double-blind, placebo-controlled crossover; well tolerated, with a rise in blood NAD+ metabolism.
• Scientific Reports, 2019: eight weeks of NR at three doses in healthy overweight adults, randomized and placebo-controlled; dose-dependent increases in whole-blood NAD+, no reports of flushing, no difference in adverse events versus placebo.
• American Journal of Clinical Nutrition, 2018: twelve weeks of high-dose NR in forty obese, insulin-resistant men; no serious adverse events, normal safety bloods, no improvement in insulin sensitivity.
• Science, 2021: ten weeks of NMN in postmenopausal women with prediabetes, randomized and placebo-controlled; increased muscle insulin sensitivity.
• GeroScience, 2023: sixty days of NMN at three doses in eighty healthy middle-aged adults, randomized and placebo-controlled; increased blood NAD+ and no safety issues on adverse-event, laboratory or clinical monitoring.
• Cell Metabolism, 2022 (the NADPARK study): a randomized phase I trial of NR in thirty newly diagnosed Parkinson's disease patients; well tolerated, with a measurable rise in cerebral NAD+.
• Nature Communications, 2024 (the NICE trial): six months of NR in ninety people with peripheral artery disease, randomized and double-blind; a modest improvement in six-minute walk distance versus placebo.

Pharmacokinetic work in Nature Communications in 2016 and PLOS ONE in 2017 described how oral NR raises blood NAD+ in healthy volunteers. Together, raising NAD+ over weeks to months in several hundred adults has been well tolerated, with no recurring adverse-event pattern.

The honest statement is short. There are no randomized controlled trials of subcutaneous NAD+ injection in humans, and there are no randomized controlled trials of intranasal NAD+ in humans. The direct human work is the six-hour intravenous pilot in Frontiers in Aging Neuroscience in 2019, designed to track metabolites rather than tolerability or outcomes; it is a pharmacokinetic study, not a safety trial, and should not be quoted as proving or disproving safety.

The remaining layer is clinical experience: subcutaneous NAD+ Injection and IV NAD+ have been used in wellness and addiction-medicine settings for years, and the side-effect pattern in the tables on this page is what prescribers and infusion clinics consistently report. That experience is real and useful, but it is uncontrolled and unpublished, and cannot establish frequencies the way a trial can. It also says nothing about years of continuous use, and nothing about whether the nasal route delivers a dose comparable to injection.

The dominant complaint with NAD+ Injection is at the needle site. NAD+ solutions are acidic and the injected volume sits in the fat layer while it absorbs, so stinging and burning during and shortly after the injection are the norm, and a small firm lump that resolves over a day or two is common. Injecting slowly, rotating between abdomen and thigh, and letting the vial come toward room temperature before drawing are the measures prescribers describe. Spreading redness, heat, or a site that is worse at 48 hours is a different problem and should be reported the same day. The lower-concentration NAD+ Injection (500 mg) exists partly for this reason: some prescribers describe it as easier on the site for people starting out. Whether it is the right starting point is your physician's decision.

NAD+ Nasal Spray sidesteps the injection site entirely. What replaces it is local: nasal irritation, a brief sting, sneezing, or drip down the back of the throat. Reviews of nasal drug delivery in the Journal of Controlled Release in 2003 and Advanced Drug Delivery Reviews in 2012 describe the limits of the route: mucociliary clearance moves most of a sprayed dose away within minutes, and only a modest fraction of a large polar molecule crosses the nasal lining. The safety consequence is favorable, since a fast systemic bolus is very hard to produce through the nose; the effectiveness consequence is that delivered dose is not equivalent to injection and has not been characterized in humans.

IV NAD+ is not something Pepti prescribes or ships; it is a clinic procedure, covered here because many people asking whether NAD+ is safe are asking because of an infusion they have had. The cluster of chest tightness, a pressured full-body sensation, flushing, abdominal cramping and nausea appears in almost every account of a fast NAD+ drip, and the standard clinic practice of starting slowly and titrating the rate up exists because of it. The symptoms are reported to ease within minutes of slowing the drip, and a well-run high-dose infusion takes hours for exactly that reason. Chest discomfort that does not resolve when the drip is slowed or stopped is not typical of the rate effect and warrants emergency evaluation.

Nausea, headache and light-headedness are reported with all three routes, usually with larger doses or faster delivery, and usually respond to a lower dose, a slower injection or a change of timing. Some people describe a wired feeling that interferes with sleep when NAD+ is taken late in the day, which is why morning dosing is commonly directed. Flushing after a dose is described clinically; the mechanism is not firmly established, and the oral NR trial in Scientific Reports in 2019 specifically reported no flushing, so it is not an inevitable property of raising NAD+. True hypersensitivity to NAD+ is not well described, but any injectable compounded product carries the possibility of a reaction to the preparation: facial or throat swelling, a widespread rash, wheeze or breathing difficulty is an emergency first and a message to your prescriber second.

NAD+ is a substrate for the PARP enzymes that repair DNA and for sirtuins that regulate cell stress responses, and the NAD+ salvage pathway is active in rapidly dividing cells. A 2019 paper in Nature Cell Biology added a specific wrinkle: it reported that NAMPT, the rate-limiting enzyme of the salvage pathway, governs the proinflammatory secretory phenotype of senescent cells in mice, and that this secretome has tumor-promoting effects. The authors concluded that NAD+ augmentation "should be administered with precision." That is a mouse finding, not a human one, and it does not show that supplemental NAD+ causes cancer in people. It does mean the question is unsettled in both directions, and that a person with an active or recent malignancy should not start NAD+ without their oncologist in the conversation. Can peptides cause cancer covers the wider question.

The 2019 infusion pilot showed that the overflow from an NAD+ dose leaves the body in the urine, as NAD+ itself and as methylnicotinamide. In a person with normal kidneys that is unremarkable. In significant chronic kidney disease the handling of that load is not characterized, and a physician is likely to want a recent creatinine and estimated GFR before prescribing NAD+ Injection and may decline if function is materially reduced. Nicotinamide, the main breakdown product, is methylated in the liver before excretion; significant liver disease is a reason for a longer conversation rather than an automatic no, and baseline liver enzymes are part of routine monitoring for that reason.

The chest tightness of a fast NAD+ infusion is understood as a rate effect in a person with a healthy heart. In someone with coronary disease, arrhythmia or heart failure, the same symptom cannot be safely attributed to the drip rate without evaluation, and the infusion chair is not the place to find out. Subcutaneous NAD+ Injection does not produce the bolus that drives this effect, which is one reason a physician may prefer it, but a cardiac history still belongs on the intake.

There is no safety data for supplemental NAD+ in pregnancy or lactation, and none of the randomized precursor trials enrolled pregnant women. It is not prescribed in either situation. See can you take peptides while pregnant.

There is no established interaction list for NAD+, because the trials that would produce one have not been run. NAD+ does not act through the liver enzymes that generate most drug interactions, and the precursor trials did not report interaction signals, but absence of evidence is not evidence of absence, which is why the intake asks for every prescription, supplement and recreational substance you use. On duration: the longest randomized precursor exposure is six months, in the NICE trial in Nature Communications in 2024, and nothing published covers years of continuous supplementation by any route. NAD+ at Pepti runs as an ongoing prescription with 28-day refills, which is exactly why monitoring is built in: the physician who prescribes it stays responsible for it.

The FDA keeps a list of bulk drug substances nominated for use in compounding under section 503A. It has three categories: Category 1, substances under evaluation; Category 2, substances that raise significant safety risks; and Category 3, substances nominated without adequate support. The list was most recently updated on 14 May 2026.

Nicotinamide adenine dinucleotide (NAD) is in Category 1, and so is its reduced form, nicotinamide adenine dinucleotide disodium reduced (NADH). A separate salt form, beta-nicotinamide adenine dinucleotide disodium salt trihydrate, is in Category 3, meaning that particular nomination was filed without enough supporting information for the FDA to evaluate it. Neither NAD nor NADH appears in Category 2, which as of the May 2026 update contains six substances, none of them NAD-related.

Category 1 means the substance was nominated with enough information for the FDA to evaluate it, that the FDA has not identified a significant safety risk that would move it to Category 2, and that a final determination on the 503A bulks list has not been made. It is the category under which compounding pharmacies have been preparing NAD+ Injection and NAD+ Nasal Spray while that evaluation is pending, under the FDA's published interim policy on compounding with nominated bulk substances. It is not approval and not an endorsement of safety; it is the FDA saying the question is open and the substance has not raised a flag.

Compounded NAD+ is not an FDA-approved drug product. No compounded medication is; approval applies to manufactured products, and compounded preparations are made by a licensed pharmacy for an individual patient against a prescription. Pepti's NAD+ products are compounded at a US FDA-registered pharmacy, with certificates of analysis published at /quality/lab-results; what that status does and does not mean is explained at /quality and in are peptides FDA approved. The 5-Amino-1MQ in the short-answer table is not NAD+; its regulatory status is covered on its own product page.